Watch as Dr David Bunka, Aptamer Group CTO, details how BLI is used within Aptamer Group’s screening and validation processes to identify the best aptamer and Optimer™ reagents, with…
2nd July 2019 Detecting and quantifying small molecule analytes can be difficult. Our specially designed displacement approach allows us to select aptamers which can directly be used in various…
5th February 2019 Aptamer Group recently collaborated with a commercial partner to develop aptamers to a variety of small molecule drugs and their active metabolites for biosensor based…
29th November 2018 This month: Aptamer Group data on selective bind and elution reusability of aptamer purification columns Small molecule analysis webinar with Pall ForteBio BLI platform Our CEO…
